Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

BAP1 (BRCA1 Associated Protein 1)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

BAP1 mutation	Mesothelioma	BAP1 mutation	Mesothelioma	tazemetostat Sensitive: C2 – Inclusion Criteria tazemetostat Sensitive : C2	tazemetostat Sensitive: C2 – Inclusion Criteria tazemetostat Sensitive : C2
BAP1 mutation	Urothelial Cancer	BAP1 mutation	Urothelial Cancer	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2
BAP1 mutation	Melanoma	BAP1 mutation	Melanoma	vorinostat Sensitive: C2 – Inclusion Criteria vorinostat Sensitive : C2	vorinostat Sensitive: C2 – Inclusion Criteria vorinostat Sensitive : C2
BAP1 negative + BRCA1 mutation	Mesothelioma	BAP1 negative + BRCA1 mutation	Mesothelioma	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3
BAP1 negative	Mesothelioma	BAP1 negative	Mesothelioma	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3
BAP1 mutation	Mesothelioma	BAP1 mutation	Mesothelioma	olaparib Resistant: C3 – Early Trials olaparib Resistant : C3	olaparib Resistant: C3 – Early Trials olaparib Resistant : C3
BAP1 mutation + FGFR2 rearrangement	Cholangiocarcinoma	BAP1 mutation + FGFR2 rearrangement	Cholangiocarcinoma	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
BAP1 mutation + FGFR2 fusion	Cholangiocarcinoma	BAP1 mutation + FGFR2 fusion	Cholangiocarcinoma	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
BAP1 mutation	Cholangiocarcinoma	BAP1 mutation	Cholangiocarcinoma	cisplatin + gemcitabine Resistant: C3 – Early Trials cisplatin + gemcitabine Resistant : C3	cisplatin + gemcitabine Resistant: C3 – Early Trials cisplatin + gemcitabine Resistant : C3
BAP1 mutation	Renal Cell Carcinoma	BAP1 mutation	Renal Cell Carcinoma	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3
BAP1 negative	Renal Cell Carcinoma	BAP1 negative	Renal Cell Carcinoma	mTOR inhibitor Sensitive: C3 – Early Trials mTOR inhibitor Sensitive : C3	mTOR inhibitor Sensitive: C3 – Early Trials mTOR inhibitor Sensitive : C3
BAP1 mutation	Renal Cell Carcinoma	BAP1 mutation	Renal Cell Carcinoma	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3